Parkman Healthcare Partners LLC Purchases New Stake in Amylyx Pharmaceuticals, Inc. $AMLX

Parkman Healthcare Partners LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the second quarter, HoldingsChannel reports. The institutional investor acquired 398,782 shares of the company’s stock, valued at approximately $7,162,000.

Several other institutional investors have also recently added to or reduced their stakes in AMLX. KBC Group NV bought a new position in shares of Amylyx Pharmaceuticals in the 1st quarter worth about $26,000. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals in the fourth quarter worth about $25,000. State of Wyoming acquired a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd boosted its stake in Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after acquiring an additional 3,493 shares during the period. Finally, California State Teachers Retirement System bought a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $28,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 1.3%

NASDAQ:AMLX opened at $38.15 on Tuesday. Amylyx Pharmaceuticals, Inc. has a 1-year low of $8.47 and a 1-year high of $41.14. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of -26.68 and a beta of -0.21. The stock has a fifty day simple moving average of $20.83 and a 200 day simple moving average of $16.87.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. HC Wainwright upped their target price on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Mizuho raised their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Citigroup upped their price target on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Buy” and an average price target of $36.25.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 10.90% of the stock is currently owned by insiders.

Amylyx Pharmaceuticals Company Profile